Literature DB >> 1648882

Amelioration of chemotherapy-induced toxicity by cotreatment with AcSDKP, a tetrapeptide inhibitor of hematopoietic stem cell proliferation.

A E Bogden1, P Carde, E D de Paillette, J P Moreau, M Tubiana, E Frindel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1648882     DOI： 10.1111/j.1749-6632.1991.tb17230.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  11 in total

1.  RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites.

Authors:  V Dive; J Cotton; A Yiotakis; A Michaud; S Vassiliou; J Jiracek; G Vazeux; M T Chauvet; P Cuniasse; P Corvol
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

2.  Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner.

Authors:  T T Myöhänen; J Tenorio-Laranga; B Jokinen; R Vázquez-Sánchez; M J Moreno-Baylach; J A García-Horsman; P T Männistö
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

3.  N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo.

Authors:  Dahai Wang; Oscar A Carretero; Xiao-Yi Yang; Nour-Eddine Rhaleb; Yun-He Liu; Tang-Dong Liao; Xiao-Ping Yang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-07-15       Impact factor: 4.733

4.  Involvement of human plasma angiotensin I-converting enzyme in the degradation of the haemoregulatory peptide N-acetyl-seryl-aspartyl-lysyl-proline.

Authors:  K J Rieger; N Saez-Servent; M P Papet; J Wdzieczak-Bakala; J L Morgat; J Thierry; W Voelter; M Lenfant
Journal:  Biochem J       Date:  1993-12-01       Impact factor: 3.857

5.  Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.

Authors:  M Azizi; A Rousseau; E Ezan; T T Guyene; S Michelet; J M Grognet; M Lenfant; P Corvol; J Ménard
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

6.  N- versus C-domain selectivity of catalytic inactivation of human angiotensin converting enzyme by lisinopril-coupled transition metal chelates.

Authors:  Lalintip Hocharoen; Jeff C Joyner; J A Cowan
Journal:  J Med Chem       Date:  2013-12-05       Impact factor: 7.446

7.  Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors.

Authors:  Megumi Kanasaki; Takako Nagai; Munehiro Kitada; Daisuke Koya; Keizo Kanasaki
Journal:  Fibrogenesis Tissue Repair       Date:  2011-11-30

8.  Usefulness of PKH fluorescent labelling to study leukemic cell proliferation with various cytostatic drugs or acetyl tetrapeptide--AcSDKP.

Authors:  Jean Boutonnat; Anne-Marie Faussat; Jean-Pierre Marie; Jérôme Bignon; Johanna Wdzieczak-Bakala; Magali Barbier; Josiane Thierry; Xavier Ronot; Pierre-Emmanuel Colle
Journal:  BMC Cancer       Date:  2005-09-20       Impact factor: 4.430

Review 9.  N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes.

Authors:  Keizo Kanasaki; Takako Nagai; Kyoko Nitta; Munehiro Kitada; Daisuke Koya
Journal:  Front Pharmacol       Date:  2014-04-14       Impact factor: 5.810

10.  Structural basis of Ac-SDKP hydrolysis by Angiotensin-I converting enzyme.

Authors:  Geoffrey Masuyer; Ross G Douglas; Edward D Sturrock; K Ravi Acharya
Journal:  Sci Rep       Date:  2015-09-25       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.